TCM
Tybourne Capital Management Portfolio holdings
AUM
$34.5M
1-Year Return
2.7%
This Quarter Return
+26.69%
1 Year Return
-2.7%
3 Year Return
+56.17%
5 Year Return
+67.69%
10 Year Return
+491.48%
AUM
$34.5M
AUM Growth
+$11M
(+47%)
Cap. Flow
+$5.68M
Cap. Flow
% of AUM
16.43%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
2
Increased
4
Reduced
–
Closed
1
Top Buys
| 1 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$4.2M |
| 2 |
BCYC
Bicycle Therapeutics
BCYC
|
$2.9M |
| 3 |
Forte Biosciences
FBRX
|
$2.15M |
| 4 |
Malibu Boats
MBUU
|
$2.09M |
| 5 |
Taysha Gene Therapies
TSHA
|
$912K |
Top Sells
| 1 |
SLRN
ACELYRIN
SLRN
|
$7.18M |
Sector Composition
| 1 | Healthcare | 93.95% |
| 2 | Consumer Discretionary | 6.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Forte Biosciences
FBRX
$137M
| $10.2M | 29.45% |
786,647
+166,666
| +27% | +$2.15M |
|
|
2
Taysha Gene Therapies
TSHA
$892M
| $9.46M | 27.39% |
4,095,000
+395,000
| +11% | +$912K |
|
|
BCYC
3
Bicycle Therapeutics
BCYC
$486M
| $6.91M | 20% |
993,743
+417,400
| +72% | +$2.9M |
|
|
ALMS
4
Alumis Inc. Common Stock
ALMS
$453M
| $4.2M | 12.15% |
+1,399,250
| New | +$4.2M |
|
|
5
Malibu Boats
MBUU
$638M
| $2.09M | 6.05% |
+66,705
| New | +$2.09M |
|
6
Zentalis Pharmaceuticals
ZNTL
$119M
| $1.71M | 4.96% |
1,478,152
+516,666
| +54% | +$599K |
|
|
SLRN
7
DELISTED
ACELYRIN
SLRN
| – | – |
-2,906,629
| Closed | -$7.18M |
|